BridgeBio Pharma Q3 2025 Financial Results and Business Updates

BridgeBio Pharma, Inc. reported its financial results for the third quarter ended September 30, 2025, and provided updates on its business operations. The company generated $120.7 million in total revenue, driven by $108.1 million in net product revenue from its commercial product, Attruby. BridgeBio highlighted the strong commercial performance of Attruby, with 5,259 unique patient prescriptions written by 1,355 unique prescribers as of October 25, 2025. The company also reported positive topline results from its Phase 3 studies for BBP-418 in LGMD2I/R9 and encaleret in ADH1, with plans to file NDAs for both in the first half of 2026. BridgeBio ended the quarter with $645.9 million in cash, cash equivalents, and marketable securities, positioning it well to continue commercializing Attruby and advancing its late-stage pipeline.